Transgenic overexpression of human LY6K in mice suppresses mature T cell development in the thymus by 源��삎�몴 et al.
ONCOLOGY LETTERS  17:  379-387,  2019
Abstract. Lymphocyte antigen 6 family member K (LY6K) is 
upregulated in a number of types of cancer and promotes tumor 
cell proliferation and metastasis. In addition, LY6K is involved 
in tamoxifen resistance in breast cancer. However, the in vivo 
molecular mechanism of LY6K has not yet been investigated. 
In the present study, transgenic mice overexpressing human 
LY6K (hLY6K) were generated using the pMAMneo vector, 
and the effect of LY6K upregulation in vivo was investigated. 
A total of 4 transgenic mice were generated, and the gene copy 
number was examined using reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR). RT-qPCR demon-
strated that mRNA of hLY6K was overexpressed in the 
thymus and spleen of the transgenic mice compared with 
wild-type mice. Flow cytometric analysis demonstrated that 
the proportions of B and T cells in the spleen were similar 
in wild-type and transgenic mice; however, the proportion of 
thymic mature T cells decreased in the transgenic mice, while 
there was an increase in the proportion of naïve T cells. These 
findings suggest that the overexpression of LY6K suppresses 
T cell development, and that LY6K is a potential therapeutic 
target for cancer.
Introduction
Ly-6/urokinase-type plasminogen activator receptors 
(uPARs) are a membrane protein superfamily character-
ized by the three‑finger fold structural motif and a putative 
glycosylphosphatidylinositol (GPI)-anchoring site (1,2). uPARs 
regulate the proteolytic degradation processes in the extracel-
lular matrix (ECM) by binding the extracellular protease 
urokinase-type plasminogen activator, which subsequently 
activates plasminogen (3). ECM molecules constitute the 
cellular microenvironment and provide mechanical support for 
cells. Furthermore, they also regulate intracellular signaling 
pathways by interacting with transmembrane proteins (4). For 
example, it was reported that ECM-integrin interaction may 
promote β cell proliferation by activating the phosphoinositide 
3-kinase cascade (5). uPAR-mediated modulation of the ECM 
is known to alter many cellular processes, including cell 
adhesion, proliferation, differentiation and migration (3,6); 
therefore, uPARs have been implicated in a number of human 
diseases, including cancer and other inflammatory diseases. 
Previous studies have demonstrated that uPARs are generally 
upregulated in cancer cells and during other inflammatory 
conditions or infections, and this makes them attractive thera-
peutic targets for the impairment of ECM-cell interactions and 
the signaling pathways of abnormal cells (1,7-9)
Lymphocyte antigen 6 family member K (Ly6K) is a 
recently discovered member of the uPAR family and was first 
identified as a molecular marker for head‑and‑neck squamous 
cell carcinoma (10). Previous studies have demonstrated that 
Ly6K is upregulated in numerous types of cancer, including 
esophageal squamous cell carcinoma, bladder cancer and 
breast cancer, and contributes to cell growth, migration, inva-
sion, and immune escape (11-14). In breast cancer, it is reported 
that Ly6K expression is regulated by the transcription factor 
activator protein-1, and that Ly6K promotes cell proliferation 
and metastasis by activating the Raf-1/MEK/ERK signaling 
pathway in cancer (15). Therefore, Ly6K has been suggested 
as a cancer biomarker and therapeutic target. Nevertheless, the 
in vivo molecular mechanism of Ly6K remains ill‑defined, and 
an appropriate in vivo mouse model to study the role of Ly6K 
has not yet been generated.
Lymphocytes are the blood cells responsible for immune 
responses. They comprise three main types: T cells, B cells, and 
natural killer cells (NK cells), which all develop from hema-
topoietic stem cells (HSC) in bone marrow (16). Lymphocyte 
development is achieved through several specific stages, 
involving coordinated regulation of lineage-associated gene 
expression, which is dependent on the type of cell (17). B cells, 
Transgenic overexpression of human LY6K in mice 
suppresses mature T cell development in the thymus
DASOM SON1*,  HYUN-KYUNG KONG1*,  YESOL KIM1,  MIN-JI SONG2,  
HYONG PYO KIM2,  HAN WOONG LEE3  and  JONG HOON PARK1
1Department of Biological Science, Sookmyung Women's University, Seoul 04310;  
2Department of Environmental Medical Biology, Institute of Tropical Medicine, Yonsei University College of Medicine;  
3Department of Biochemistry, Yonsei University, Seoul 03722, Republic of Korea
Received March 1, 2017;  Accepted January 17, 2018
DOI:  10.3892/ol.2018.9548
Correspondence to: Professor Jong Hoon Park, Department of 
Biological Science, Sookmyung Women's University, 100 Cheongpa-ro 
47-gil, Yongsan-gu, Seoul 04310, Republic of Korea
E-mail: parkjh@sookmyung.ac.kr
*Contributed equally
Key words: lymphocyte antigen 6 family member K, lymphocytes, 
T cell development, thymus, spleen, breast cancer, transgenic mouse 
model
SON et al:  OVEREXPRESSION OF LY6K SUPPRESSES THYMIC MATURE T CELL DEVELOPMENT380
which mediate the humoral immune response by producing 
antibodies, undergo full development in the bone marrow via 
immunoglobulin gene rearrangement, whereas T cell develop-
ment occurs distal to the bone marrow (18). HSCs migrate from 
the bone marrow to the thymus and continue to proliferate to 
generate a large group of immature thymocytes, which lack 
T-cell receptor (TCR) expression. These cells do not express 
CD4 or CD8, and are therefore termed double-negative (DN) 
cells (19). Following several developmental stages, cells that 
achieve pre-TCR expression develop into double-positive 
CD4+CD8+ cells. These cells then become single-positive 
thymocytes (CD4+CD8- or CD4-CD8+), depending on the 
interaction between the TCR and the major histocompatibility 
complex (MHC) ligand on the epithelial cells (20,21).
Despite the strong association between Ly6K and 
cancer development, in vivo models to examine the 
effect of Ly6K expression on tumors have not yet been 
developed. In the present study, a transgenic mouse model 
overexpressing the human LY6K (hLY6K) gene was generated 
to investigate the changes resulting from LY6K overexpression 
in vivo. Mouse mammary tumor virus (MMTV)/hLY6K trans-
genic mice expressed LY6K mRNA strongly in the thymus 
and spleen. Flow cytometric analysis demonstrated that the 
levels and distribution of cytotoxic and helper T cells were 
decreased in the transgenic mouse, which indicated that T cell 
development was defective when LY6K was overexpressed.
Materials and methods
Generation of LY6K transgenic mice. The construct to 
generate the transgenic mice was produced by inserting human 
LY6K cDNA, which was previously described (22), into the 
pMAMneo vector (Clontech Laboratories, Inc., Mountainview, 
CA, USA). The full-length human LY6K cDNA fragment 
was amplified by polymerase chain reaction (PCR) under the 
following thermocycling conditions: Initial denaturation at 
98˚C for 5 min, 35 cycles at 98˚C for 10 sec, 50˚C for 50 sec 
and 72˚C for 20 sec; and final extension at 72˚C for 5 min. 
For PCR, Taq Polymerase, dNTPs and reaction buffers (Real 
Biotech Corporation, Taipei, Taiwan) were used according to 
the manufacturer's protocol. Specifically-designed primers 
containing NheI or XhoI restriction enzyme sites were used 
and the sequences were as follows: Forward, 5'-CTA GCT AGC 
ATG GCG CTG CT-3'; and reverse, 5'-GGC CTC GAG TCA AGA 
CAG GC-3'. Fragments digested with NheI and XhoI restriction 
enzymes (New England Biolabs, Ipswich, MA, USA) were 
purified by the HiYield Gel/PCR extraction kit (Real Biotech 
Corporation) according to the manufacturer's protocol, and 
then inserted into the corresponding restriction sites of the 
vector. The recombinant construct carrying the transgene was 
microinjected into the pronuclei of fertilized eggs of B6 mice 
(Animal Facility, Sookmyung Women's University, Seoul, 
Korea), and the eggs were then transferred into the oviducts of 
pseudo-pregnant female mice. Transgenic founder mice were 
bred with B6 mice to establish transgenic lines; a total of 7 
founder mice (8-9 weeks-old; average weight, ~20 g) were 
generated. All mice were housed in a specific pathogen‑free 
barrier facility with a 12 h light/dark cycle and maintained at a 
humidity of 40‑60% at 23˚C. Mice had ad libitum access to food 
and water. After 6 weeks, mice were euthanized by cervical 
dislocation for further analysis. All animal experiments were 
approved by the Institutional Animal Care and Use Committee 
at the Sookmyung Women's University (Seoul, South Korea).
Genomic DNA extraction and PCR. Genomic DNA was 
extracted from the tail biopsies of each mouse using a 
Quick-DNA™ Universal Kit (Zymo Research, Irvine, CA, 
USA) according to the manufacturer's protocol. To confirm 
the presence of the transgene, PCR was performed to amplify 
specific fragments of the hLY6K gene. The sequences of the 
primers used were as follows: Forward, 5'-TGT GGT TTA 
GGT TGG AGT GTA GTG-3'; and reverse, 5'-CTC ATC AAA 
AAA ATC TCC CCA AC-3'. EmeraldAmp® GT PCR Master 
Mix (Clontech Laboratories, Inc.) was used to amplify DNAs 
according to the manufacturer's protocol. The thermocycling 
conditions were as follows: Initial denaturation step for 2 min 
at 95˚C, 30 cycles for 30 sec at 95˚C, 30 sec at 58˚C and 30 sec 
at 72˚C, and the final extension step for 5 min at 72˚C. The 
amplified DNA samples were resolved on a 1.0% agarose gel 
and separated by electrophoresis at 200 V for 40 min, which 
produced bands of 360 bp. To compare the amount of the 
transgene, standard samples containing 1, 10 and 100 copies 
of the transgene were prepared and mixed with the genomic 
DNA of wild‑type B6 mice, then amplified and separated on 
the same agarose gel.
Quantitative PCR (qPCR) evaluation of transgene copy 
number. To examine the copy number of the transgene, a 
standard curve was generated using 1, 10 and 100 copies of 
the transgene diluted in the genomic DNA of wild-type mice. 
qPCR was performed using SYBR-Green qPCR Master 
Mix (PCR Biosystems, Ltd., London, UK), and each reac-
tion sample contained the following components: 100 ng 
genomic DNA, 10 µM of each primer and 5 µl SYBR Green 
qPCR Master Mix. The sequence of the primers used were 
as follows: hLY6K forward, 5'-AGC CCA TGC CCT TCT TTT 
ACC TCA-3'; and hLY6K reverse, 5'-CCA GCC ACA GCC CAC 
CAC AG-3'; mouse Gapdh (mGapdh) forward, 5'-GCT GAG 
TAT GTC GTG GAG TC-3'; and mGapdh reverse, 5'-ATG GAC 
TGT GGT CAT GAG C-3'. The mGapdh gene was amplified 
as an endogenous control. qPCR cycling conditions were as 
follows: A pre‑incubation step of 10 min at 95˚C; followed 
by 45 amplification cycles of 10 sec at 95˚C, 10 sec at 60˚C, 
and 10 sec at 72˚C; and a final elongation step of 1 min at 
65˚C. The standard curve was determined by plotting ΔCq 
(ΔCq=CqhLY6K-CqGapdh) against the log of hLY6K gene copies 
of the corresponding standard samples, and the copy numbers 
of the transgene in transgenic mice were determined by the 
2-ΔΔCq method (23). The formula was as follows: 2-ΔΔCq=2-(ΔCq of 
transgenic samples-ΔCq of wild-type samples) (24).
RNA isolation and reverse transcription (RT). RNAs were 
extracted from each tissue of 3 mice per group (wild-type and 
transgenic mice) using a NucleoSpin® DNA/RNA/Protein 
kit (Machery-Nagel GmbH, Düren, Germany), according to 
the manufacturer's protocol. RNAs (2 µg) diluted in 12.5 µl 
of sterile RNase free water were reverse transcribed to 
cDNAs using an M-MLV Reverse Transcription kit (Promega 
Corporation, Madison, WI, USA) at 42˚C for 1 h and then 
inactivated at 70˚C for 10 min.
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RT‑PCR. Following RT, as described above, cDNA samples 
(100 ng) were used as templates to amplify specific frag-
ments with RBC Taq Polymerase, and each reaction mixture 
contained the following: 3 µl 10X RBC Reaction Buffer, 3 µl 
dNTPs (2.5 mM), 10 mM of each primer, 100 ng of cDNA, 
1 µl RBC Taq Polymerase and 21.7 µl double-distilled water. 
The sequences of the primers used to detect hLY6K or 
mGapdh were as follows: hLY6K forward, 5'-TGC TCG CCT 
TGC TGC TGG TC-3'; hLY6K reverse, 5'-TCG CTG CAC AAC 
CAG CGG AG-3'; mGapdh forward, 5'-CGG TGC TGA GTA 
TGT CGT GGA G-3'; and mGapdh reverse, 5'-TGT CAT CAT 
ACT TGG CAG GTT TC‑3'. Amplification condition were as 
follows: Initial denaturation step for 2 min at 95˚C, 30 cycles 
for 30 sec at 95˚C, 30 sec at 58˚C and 30 sec at 72˚C; and the 
final extension step for 5 min at 72˚C. Following amplification, 
the PCR products were separated on 1.0% agarose gels by 
electrophoresis at 200 V for 40 min.
RT‑qPCR. To further compare the RNA expression level 
of hLY6K in wild-type and transgenic mice, RT-qPCR 
was conducted using SYBR Green qPCR Master Mix 
(PCR Biosystems, Ltd.). cDNA samples (100 ng) were used as 
templates, and the sequences of the primers to detect hLY6K 
and mouse Gapdh were same as those used to examine the 
transgenic copy number. qPCR cycling conditions were as 
follows: A pre‑incubation step of 10 min at 95˚C; 45 amplifica-
tion cycles of 10 sec at 95˚C, 10 sec at 60˚C and 10 sec at 
72˚C; and a final elongation step of 1 min at 65˚C. The rela-
tive expression levels of hLY6K were calculated by the 2-ΔΔCq 
method, normalized against the level of mGapdh.
Western blot analysis. To obtain proteins from the mouse 
tissues, tissues was disrupted and homogenized with lysis 
buffer RP1 (Macherey-Nagel GmbH & Co., Düren, Germany) 
containing 1% β-mercaptoethanol (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA) and stainless steel beads using 
TissueLyser (Qiagen GmbH, Hilden, Germany) at 1500 oscil-
lations/min for 1 min at room temperature. Protein extracts 
were prepared using a NucleoSpin® DNA/RNA/Protein kit 
and buffers included in kit (Macherey-Nagel GmbH & Co.), 
according to the manufacturer's protocol. Protein extracts were 
dissolved with Protein Solving Buffer containing the reducing 
agent TCEP (Macherey-Nagel GmbH & Co.) and boiled at 
98˚C for 3 min. The protein concentration was measured 
using a bicinchoninic acid solution and copper (II) sulfate 
solution (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). 
Samples were loaded (30 µg/lane) and separated by SDS-PAGE 
(10-12% gel) and transferred onto polyvinylidene fluoride 
membranes. Membranes were blocked with 5% skim milk in 
PBS containing 0.2% Tween-20 for 1 h at room temperature. 
Immunoblotting was conducted using an anti-Ly6K antibody 
(cat no. sc-87282; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) for the detection of human and mouse Ly6K, and an 
anti-β-actin antibody (cat no. A300-491A; Bethyl Laboratories, 
Montgomery, TX, USA), which were diluted at 1:1,000 in 1% 
skim milk in PBS containing the detergent 0.2% Tween-20 
overnight at 4˚C. Horseradish peroxidase‑conjugated goat 
anti-rabbit secondary antibody (cat no. ADI-SAB-300-J; Enzo 
Life Science, Inc., Farmingdale, NY, USA) was used and diluted 
at 1:4,000 in 2% skim milk in PBS containing the detergent 
0.2% Tween-20 for 1 h at room temperature. Immunoreactive 
proteins were detected using the enhanced chemilumines-
cence reagent EzWestLimiplus (cat no. WSE-7120; ATTO 
Corporation, Tokyo, Japan).
Flow cytometric analysis. Cell populations were isolated from 
the thymus or spleen of the transgenic mouse and investigated 
by flow cytometry. Cells were washed with 1X PBS and then 
fixed with 70% ethanol overnight at 4˚C. To examine the expres-
sion of surface markers of thymocytes, cells were stained with 
specific antibodies targeting surface markers of lymphocytes: 
Conjugated PerCP-Cy5.5-anti-CD44 (cat no. 45-0441-82; 
Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, 
USA), conjugated allophycocyanin (APC)-anti-CD25 
and conjugated APC-anti-B220 (cat nos. 17-0251-82 and 
17‑0452‑82; all from Invitrogen; Thermo Fisher Scientific, 
Inc.), conjugated PE-anti-CD4 and conjugated fluorescein 
isothiocyanate-anti-CD8 (cat nos. ab134354 and ab28010; 
all from Abcam). All antibodies were diluted 1:200 in FACS 
buffer (1X PBS containing 1% BSA) and incubated with each 
sample for 30 min on ice. Analysis was conducted using a 
FACSCanto II flow cytometer (BD Biosciences, Franklin 
Lakes, NJ, USA) and data were analyzed using FlowJo 7.6.5 
software (Tree Star, Inc., Ashland OR, USA).
Statistical analysis. All experiments were repeated three 
times independently. Statistical analyses were performed using 
GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, 
CA, USA). The data are presented as the mean ± standard 
deviation. The RT-qPCR data were analyzed by Student's 
t-test, and the other data were examined by a two-way analysis 
of variance followed by a Bonfferoni post-hoc test. P<0.05 was 
considered to indicate a statistically significant difference.
Results
hLY6K was successfully overexpressed in transgenic mice. 
To investigate the function of human LY6K on mammary 
development in vivo, transgenic mice overexpressing the 
human LY6K gene were established. We generated transgene 
construct for the full-length human LY6K gene downstream 
of the MMTV-long terminal repeat (MMTV-LTR) promoter 
(Fig. 1A). The transgene was injected into fertilized mouse 
eggs, which were then transferred into the oviducts of female 
mice. The potential founder mice were crossed with C57BL/6 
(B6) mice, and 7 transgenic mouse lines were generated. 
Genomic DNAs extracted from the transgenic mice were 
amplified by PCR with human LY6K-specific primers. As 
shown in Fig. 1B, 4 of the 7 transgenic mice carried the hLY6K 
transgene. To further examine the copy number of the hLY6K 
transgene, qPCR was performed, revealing that transgenic 
mouse B had the highest expression of the transgene (Fig. 1C), 
and this was used for further study.
hLY6K expression in the tissues of transgenic mice. To 
determine the tissue specificity of the transgene expression, 
the RNA levels of hLY6K were examined in wild-type and 
transgenic mice by RT-PCR (Fig. 2A). Tissues were harvested 
from the thymus, spleen, mammary gland and other organs of 
6-week-old virgin mice, and RNAs were extracted from each 
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Figure 2. hLY6K mRNA levels in tissues of WT mice and Tg mouse B. (A) hLY6K mRNAs were extracted from each tissue and subjected to RT-PCR. The 
amplified fragments were size‑separated using an agarose gel. mGapdh was used as the loading control. (B) The mRNA expression levels of hLY6K in the 
thymus and spleen were analyzed by RT-qPCR. The relative mRNA levels of hLY6K were determined by normalizing against the level of mGapdh. (C) The 
protein levels of LY6K in the thymus and spleen were analyzed by western blotting. β-actin was used as the loading control. Data are presented as the 
mean ± standard deviation; ***P<0.001, and *P<0.05 (t-test). hLY6K, human lymphocyte antigen 6 family member K; WT, wild-type; Tg, transgenic; RT-qPCR, 
reverse transcription-quantitative polymerase chain reaction; mGapdh, mouse glyceraldehyde 3-phosphate dehydrogenase.
Figure 1. Generation and identification of transgenic mice. (A) Schematic diagram of a transgene construct for the hLY6K gene. The full-length hLY6K cDNA 
was placed under the control of the MMTV promoter. (B) PCR analysis using hLY6K gene‑specific primers. Genomic DNAs extracted from seven transgenic 
mice (lanes 1‑7) were amplified and size‑separated on an agarose gel. The presence of the transgene was detected in genomic DNA from 4 of the mice, 
designated A, B, C, and D. PCR bands of the transgene construct mixed with WT genomic DNA are shown as the standard. (C) The copy number of the hLY6K 
transgene in founder mice. Genomic DNA was subjected to qPCR with primers specific to the hLY6K gene, and the signals of the transgene were normalized 
to those of mouse Gapdh, an endogenous control. Data are presented as mean ± standard deviation. hLY6K, human lymphocyte antigen 6 family member K; 
WT, wild-type; bp, base pairs; pMMTV-LTR, mouse mammary tumor virus long terminal repeat promoter; qPCR, quantitative polymerase chain reaction.
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tissue sample, which were subsequently analyzed by RT-PCR. 
To avoid the detection of mouse LY6K instead of human LY6K, 
their sequences were compared using NCBI nucleotide BLAST, 
and there was no significant similarity except for the Ly‑6/uPAR 
domain [(25), https://blast.ncbi.nlm.nih.gov/Blast.cgi; human 
LY6K gene accession number, NM_017527; mouse LY6K 
gene accession number, NM_029627]. Thus, PCR primers 
were designed to recognize only human LY6K mRNA but 
not the endogenous mouse LY6K, and it was confirmed 
that hLY6K‑specific primers only amplified LY6K mRNAs 
extracted from human cell lines but not those from mouse 
cells (data not shown). Amplified products were separated on 
the agarose gel. As Fig. 2A illustrates, the mRNA expression 
of hLY6K was detected strongly in the thymus and weakly 
in the spleen and lung, while other tissues, including the 
mammary gland, displayed no expression of the transgene. 
For further examination, RT-qPCR was performed to quanti-
tatively compare the RNA level of hLY6K in the wild-type and 
transgenic mice. RNAs extracted from the thymus and spleen 
were examined and, as indicated in Fig. 2B, the relative RNA 
expression of hLY6K was markedly increased in the thymus 
and spleen of the transgenic mouse compared with those of the 
wild-type mice. Furthermore, western blot analysis revealed 
that the transgenic mouse had markedly higher protein levels 
of Ly6K in the thymus and spleen compared with those of 
wild-type mice (Fig. 2C). These results indicated that the 
hLY6K transgene with the MMTV promoter was expressed 
specifically in the thymus and spleen, rather than in other 
tissues, including the mammary gland.
Effect of hLY6K overexpression on lymphocyte development 
in the spleen. As previously stated, the hLY6K transgene was 
significantly expressed in the spleen of the transgenic mouse 
examined. The spleen filters and generates blood cells; however, 
it is also involved in lymphocyte proliferation and activation 
as one of the major sites where blood-circulating antigens are 
presented to lymphocytes in order to generate an immune 
response (26). Therefore, the present study investigated whether 
the overexpression of hLY6K caused any changes to lympho-
cytes in the spleen. First, the distribution of T cells was verified 
according to the expression of CD4 and CD8, the surface 
markers of mature T cells. As shown in Fig. 3A, including 
helper T cells (CD8-CD4+) and cytotoxic T cells (CD8+CD4-), 
the proportion of each cell type did not exhibit any significant 
Figure 3. Distribution of T cells and B cells in the spleen of Tg mouse B and WT mice. Flow cytometric analysis was conducted to examine the distribution 
of T and B cells. The proportion of each cell type is shown in the graph, and the numbers represent the percentages of quadrant analysis. (A) Distribution of 
splenic T cells in the WT and Tg mice. Antibodies specific for CD4 or CD8 were used to identify the different types of T cells. (B) The distribution of splenic 
B cells (B220+CD25-) in the WT and Tg mice. Antibodies against B220 or CD25 were used to identify mature B cells. WT, wild-type; Tg, transgenic; LY6K, 
lymphocyte antigen 6 family member K; DN, double-negative (CD4-CD8-); DP, double-positive (CD4+CD8+); Th, helper T cells (CD4+CD8-); Tc, cytotoxic 
T cells (CD4-CD8+).
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change in the spleen compared with the levels in wild-type 
mice. B cell populations in the spleen were then investigated 
by analyzing the expression of B220, a murine B cell marker, 
and CD25, the α chain of the IL-2 receptor (27) (Fig. 3B). 
Normally, CD25 expression is characteristic of CD4+FoxP3+ 
regulatory T cells in mice and only 2% of B cells express CD25 
in the spleen (28). As shown in Fig. 3B, there was no significant 
change in the proportion of B220+ and CD25- B cells between 
the wild‑type and transgenic mice. These findings implied that 
the overexpression of hLY6K did not have a significant effect on 
lymphocyte development in the spleen.
Effect of LY6K overexpression on T cell development in the 
thymus. The expression of hLY6K was detected in the spleen 
and in the thymus (Fig. 2). The thymus is a specialized lymphoid 
organ where T cell development occurs. Therefore, the present 
study investigated whether hLY6K overexpression influenced 
T cell development in the transgenic mouse. DN naïve T 
cells, which are negative for CD4 and CD8 expression, can be 
subdivided into four subgroups (DN1-DN4) depending on their 
expression of CD44 and CD25 (29). Flow cytometric analysis 
was conducted to examine the expression of CD44 and CD25 
in thymocytes isolated from wild-type and transgenic mice, and 
cells were categorized depending on the expression of those 
markers. Fig. 4A demonstrates the distribution of early naïve T 
cells in the thymus of wild-type and transgenic mice. The present 
study identified that the proportion of the DN2 (CD25+CD44+) 
subgroup was decreased markedly in the transgenic mouse 
compared with wild-type mice, whereas the DN1 (CD25-CD44+) 
and DN3 (CD25+CD44-) populations exhibited no significant 
differences. Notably, the DN4 (CD25-CD44-) population was 
markedly increased in the transgenic mouse, suggesting that 
more naïve T cells had completed TCR rearrangement and 
had begun to express CD4 and CD8 molecules for the next 
stage of development. Therefore, the levels of CD4 and CD8 
(surface markers of mature T cells) were examined in the thymic 
T cells of each type of mouse to compare further developmental 
steps (Fig. 4B). The results revealed that the double positive 
(CD4+CD8+) subgroup was increased in the transgenic mouse, 
as hypothesized. However, the proportions of cytotoxic T cells 
(CD8+CD4-) and helper T cells (CD8-CD4+) were decreased in 
the transgenic mouse. This implied that fewer T cells were fully 
differentiated in the transgenic mouse, when hLY6K was overex-
pressed, compared with the wild-type mice, despite an increased 
number of lymphocytes undergoing TCR rearrangement.
Discussion
Ly6K is known to be upregulated in numerous types of 
cancer and its increased expression is associated with a poor 
Figure 4. Distribution of T cells in the thymus of the WT and Tg mice. The distribution of T cells was confirmed by flow cytometric analysis. (A) The distribu-
tion of naïve T cells in WT and Tg mice was examined using antibodies specific for CD44 or CD25. (B) The proportion of each type of mature T cell was 
analyzed using antibodies specific for CD4 or CD8. Data are presented as the mean ± SD; ***P<0.001, and **P<0.01 (t-test). WT, wild-type; Tg, transgenic; 
LY6K, lymphocyte antigen 6 family member K; DN1, CD44+CD25-; DN2, CD44+CD25+; DN3, CD44-CD25+; DN4, CD44-CD25-; DN, double-negative 
(CD4-CD8-); DP, double-positive (CD4+CD8+); Th, helper T cells (CD4+CD8-); Tc, cytotoxic T cells (CD4-CD8+).
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outcome in patients with cancer (30). In our previous study, 
Ly6K expression was identified to be inversely associated with 
estrogen receptor α (ERα) levels, suggesting that high expres-
sion of Ly6K may result in tamoxifen resistance of cancer 
cells (31). Furthermore, it was recently reported that Ly6K/E 
signaling involving transforming growth factor β promotes 
cancer progression and drug resistance in breast cancer (14). 
Therefore, Ly6K is considered to be both a prognostic marker 
and a therapeutic target in cancer, particularly in breast 
cancer (14), and a number of studies have been conducted on the 
molecular mechanism of LY6K in vitro. However, the in vivo 
mechanism of LY6K has received little attention. Therefore, 
in the present study, a transgenic mouse model overexpressing 
the hLY6K gene was constructed to investigate the effects of 
hLY6K overexpression in vivo.
hLY6K cDNA was inser ted downstream of the 
MMTV-LTR promoter, which was subsequently injected into 
the mouse embryo to generate hLY6K transgenic C57BL/6 
mice. The C57BL/6 mouse is one of the most commonly used 
animal models for human diseases (32). Since they have a 
relatively long life-span, are easy to breed, and are permis-
sive for maximal expression of the majority of mutations, they 
are widely used to generate transgenic mice (33). MMTV is 
a milk-transmitted infectious agent involved in mammary 
epithelial cell tumors in mice (34). It was originally identi-
fied as an endogenous murine retrovirus, and has been used 
to generate animal models for the study of human cancer 
due to its LTR sequence flanking the MMTV genome and its 
ability to direct the expression of downstream genes (35,36). In 
particular, it can induce gene expression in mammary epithe-
lial cells; therefore, MMTV-LTR has been widely used to 
generate transgenic mice overexpressing an exogenous gene in 
the mammary gland for the study of human breast cancer (37). 
Furthermore, as MMTV is expressed in other organs, 
including the salivary glands, lungs, spleen, and thymus, a 
transgene under the control of the MMTV-LTR promoter can 
be expressed in organs other than mammary glands (38,39).
In the present study, the human LY6K gene was inserted 
downstream of MMTV-LTR to generate transgenic mice, 
which resulted in the overexpression of hLY6K in the thymus 
and the spleen, but not in the mammary glands. Notably, it 
has been reported that MMTV-LTR activity is regulated by 
hormones of pregnancy, such as glucocorticoids and prolactin, 
and increases during pregnancy and lactation (40). It was also 
demonstrated that the MMTV promoter did not facilitate 
transgene expression in the virgin mammary glands, and 
the gene only began to be expressed during pregnancy and 
lactation in the examined mice (40,41). Considering that the 
transgenic mouse used in the present study was a 6-week-old 
virgin mouse, the lack of transgene expression in the mammary 
glands was attributed to the lack of pregnancy hormones 
responsible for the activity of the MMTV promoters. However, 
high expression of hLY6K gene was validated by qPCR anal-
ysis in the thymus and spleen of the transgenic mouse using 
hLY6K‑specific primers.
The thymus and the spleen are the principal sites for 
lymphocyte development; therefore, the present study 
investigated whether the overexpression of hLY6K induced 
any defects in lymphocyte generation. Although hLY6K 
overexpression did not cause any significant changes in the 
distribution of lymphocytes in the spleen, the proportions of 
various types of functional mature T cells were decreased 
markedly in the thymus of the transgenic mouse. The increase 
in the DN4 (CD25-CD44-) population in the transgenic mouse, 
which implied that more premature T cells had undergone 
TCR rearrangement, suggested that T cell maturation was 
defective when hLY6K was overexpressed.
CD8+ cytotoxic T cells and CD4+ helper T cells are 
known to perform antitumor functions in numerous types of 
cancer (42,43). Cytotoxic T cells can specifically eliminate 
infected cells that present antigens bound to MHC class I mole-
cules, which are recognized by cytotoxic T cells (44). Notably, 
the majority of cancer cells express MHC class I molecules; 
therefore, tumor antigen‑specific cytotoxic T cells can infiltrate 
tumor sites and attack tumor cells specifically by recognizing 
the antigens linked with MHC molecules (45,46). In addition, 
CD4+ helper T cells, which aid the adaptive immune response 
of other immune cells by releasing cytokines, are reported to be 
required for effective antitumor immunity (47,48). In addition 
to their ability to maintain immune responses to tumor cells by 
helping cytotoxic T cells and other immune cells, helper T cells 
are also able to kill cancer cells directly, as mutated or fusion 
proteins in cancer cells generate MHC class II molecules that 
are recognized by helper T cells (49,50). Therefore, the immune 
responses mediated by the different types of T cells execute 
protective mechanisms against cancer.
The experimental results demonstrating the decrease of the 
functional T cell population under Ly6K overexpression in the 
thymus indicated that Ly6K may negatively regulate normal 
T cell differentiation, which in turn may lead to the suppres-
sion of the antitumor effect of immune cells.
As previously stated, a number of studies have demonstrated 
that Ly6K is upregulated in numerous types of cancer and posi-
tively regulates tumor progression. However, the expression 
patterns and function of Ly6K in the thymus of patients with 
cancer have not yet been investigated. Considering the poten-
tial negative effect of Ly6K on antitumor immunity identified 
in the present study, further studies are required to investi-
gate whether Ly6K expression is upregulated in the thymus 
of patients with cancer and whether Ly6K overexpression 
suppresses the generation of functional lymphocytes.
Notably, it has been reported that uPAR expression is 
increased to a greater extent in regional lymph node metastasis 
than in the primary intraprostatic tumor mass (51). Given that 
thymic metastasis occurs in several types of cancer, including 
breast cancer (52-54), the expression of Ly6K in the thymus 
may be altered by the metastasis from the primary tumor 
mass in these cancer patients. Together with its own oncogenic 
effect, the potential role of Ly6K in T cell development and 
anticancer immunity makes it a promising therapeutic target 
in human cancer.
In conclusion, the present in vivo study demonstrated that 
Ly6K has the potential to suppress the immune response 
against tumor cells by inhibiting T cell development. However, 
the present study did not reveal the molecular mechanisms of 
Ly6K in T cell development. Therefore, further investigation on 
Ly6K at the molecular level is required in order to demonstrate 
the involvement of the Ly6K pathway in lymphocyte develop-
ment. Additionally, the effect of Ly6K on the antitumor immune 
response in patients with cancer should be studied to fully 
SON et al:  OVEREXPRESSION OF LY6K SUPPRESSES THYMIC MATURE T CELL DEVELOPMENT386
understand the role of Ly6K in human cancer. Eventually, Ly6K 
might provide an effective therapeutic target to treat cancer.
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